www.horizonscan.nl gebruikt cookies om het gebruik van de website te analyseren en het gebruiksgemak te verbeteren. Lees meer over
cookies
op www.rijkshuisstijl.nl
Sluiten
You are here:
Horizonscan geneesmiddelen
Medicines
Search the site
Search
Hematology
All latest versions
3 December 2024
4 June 2024
5 December 2023
6 June 2023
7 December 2022
7 June 2022
Compact view
Extended view
Grouped by indication
Grouped by status
Grouped by reason of inclusion in Horizonscan Geneesmiddelen
Grouped by submission date
Grouped by expected registration date
Grouped by manufacturer
Grouped by mechanism of action
Grouped by particularity
Grouped by registration phase
Grouped by publication date
Ungrouped
Filters
Sluit
Registration
Show ATMPs only
Show Orphan drugs only
Mechanism of action
Any mechanism of action
Unknown
Alkylating agent
Allergen
Allogeneic modified cell therapy
Amino acid
Anesthetic
Angiogenesis inhibitor
Antiandrogen
Antibiotic
Antibody-drug conjugate
Anticoagulant
Antifungals
Antihistamine
Antioxidant
Antisense oligonucleotide
Autologous modified cell therapy
Bcl-2 inhibitor
BET inhibitor
Calcineurin inhibitor
Cancer vaccine
Cannabinoid
CAR-T therapy
CDK4 / 6 tyrosine kinase inhibitor
CFS1R inhibitor
CGRP-directed antibody
Chelating agent
Coagulant
Combination therapy
Complement inhibitor
Corticosteroid
CTLA-4 antibody
Cytostatic
Disinfectant
Enzyme
Enzyme inhibitor
Enzyme replacement therapy
Gene therapy
GLP-1 receptor agonist
Glucagon analogue
Growth factor
HIV inhibitor
Hormonal therapy
Immunostimulation
Immunosuppression
Insulin preparation
Interferon inhibitor
Interleukin inhibitor
Ion channel blocker
JAK tyrosine kinase inhibitor
LABA / ICS
LABA / LAMA
LABA / LAMA / ICS
LAMA
MEK kinase inhibitor
Neurotoxin
Neurotransmitter
Oncolytic adenovirus
Other
Other, see general comments
PARP inhibitor
PD-1 / PD-L1 inhibitor
Proteasome inhibitor
Protein chaperone
Receptor agonist
Receptor antagonist
Serine / threonine kinase inhibitor
SGLT inhibitor
Small interfering RNA (siRNA)
Sodium channel blocker
Thrombin inhibitor
TNF-alpha inhibitor
Tyrosine kinase inhibitor
Vasodilator
Virus inhibitor
Budgetting framework
Any budgetting framework
Unknown
Extramural (GVS)
Intermural (MSZ)
Particularity
Any particularity
Unknown
New medicine with Priority Medicines (PRIME)
New therapeutical formulation
Reason of inclusion
New medicines
Indication extensions
IND
Biosimilars / generics
BS
G
Download
ALL
Blinatumomab
IND
Brexucabtagene autoleucel
IND
Obecabtagene autoleucel
AML / MDS
Decitabine / cedazuridine
IND
Imetelstat
Iodine (131I) apamistamab
Luspatercept
IND
Magrolimab
Olutasidenib
Revumenib
Tamibarotene
Aggressive non-Hodgkin’s lymphoma
Acalabrutinib
Mantle cell lymphoma (MCL), 1L. Calquence in combination with bendamustine and rituximab (BR) is indicated for the treatment of adult patients with previously untreated MCL
IND
Acalabrutinib monotherapy for second line or later treatment of relapsed or refractory mantle cell lymphoma in adults and elderly
IND
Axicabtagene ciloleucel
IND
Crizotinib
IND
Epcoritamab
Glofitamab
Columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B‑cell lymphoma (DLBCL), after two or more lines of systemic therapy.
Glofitamab in combinatie met gemcitabine en oxaliplatine voor de behandeling van volwassen patiënten met recidiverende of refractaire diffuus groot B-cellymfoom (DLBCL), na één of meerdere lijnen systemische therapie.
IND
Ibrutinib
IND
Lisocabtagene maraleucel
Breyanzi voor de behandeling van recidief of refractair grootcellig B-cellymfoom (R/R DLBCL), primair mediastinaal B-cellymfoom (PMBCL), en folliculair lymfoom graad 3B (FL3B), na twee of meer lijnen systemische therapie
Breyanzi is indicated for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL), high grade B cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.
IND
Loncastuximab tesirine
Odronextamab
Polatuzumab vedotin
IND
Tafasitamab
MINJUVI is indicated in combination with lenalidomide followed by MINJUVI monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT)
Tafasitamab in combinatie met lenalidomide is geïndiceerd in combinatie met rituximab, cyclofosfamide, doxorubicine, vincristine en prednison (R-CHOP) voor de behandeling van volwassen patiënten met onbehandeld diffuus grootcellig B-cellymfoom (DLBCL).
IND
Zamtocabtagene autoleucel
CLL
Acalabrutinib
IND
Iopofosine I 131
Pirtobrutinib
IND
Zanubrutinib
Extension of indication to include treatment of adult patients with chronic lymphocytic leukaemia (CLL).
IND
Extension of indication to include treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one-prior anti-CD20-based therapy
IND
CML
Bosutinib
IND
Graft versus Host
Belumosudil
MaaT013
Ruxolitinib
Hodgkin's lymphoma
Brentuximab vedotin
IND
Indolent non-Hodgkin’s lymphoma
Epcoritamab
IND
Lacutamab
Lisocabtagene maraleucel
IND
Mosunetuzumab
IND
Tafasitamab
IND
Zanubrutinib
IND
Multiple Myeloma
Belantamab mafodotin
Multiple Myeloma 3L
IND
Second line treatment of r/r multiple myeloma in adults and elderly, in combination with bortezomib and dexamethasone, or pomalidomide and dexamethasone
IND
Ciltacabtagene autoleucel
IND
Daratumumab
Extension of indication for Darzalex in combination with bortezomib, lenalidomide and dexamethasone for the treatment of newly diagnosed multiple myeloma, to include also adult patients who are not eligible for stem cell transplant (SCT)
IND
In combination with bortezomib, lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant
IND
Elranatamab
Idecabtagene vicleucel
IND
Isatuximab
Extension of indication to include in combination with bortezomib, lenalidomide, and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
IND
In combination with bortezomib, lenalidomide and dexamethasone (Isa VRd) in patients with newly diagnosed multiple myeloma (NDMM) eligible for transplant.
IND
Isatuximab in combination with pomalidomide and dexamethasone for second line or later treatment of relapsed and/or refractory multiple myeloma in adults and elderly who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitor
IND
Selinexor
IND
Talquetamab
Teclistamab
Venetoclax
IND
Myeloproliferative disorders
Avapritinib
IND
Momelotinib
Navitoclax
Pacritinib
Peginterferon alfa-2a
IND
Pelabresib
Pemigatinib
IND
Pivekimab Sunirine
Other hematology
Lenzilumab
Stem cell transplants
Dorocubicel
Nomacopan
Naar boven
National Health Care Institute
Login
Understanding of expected market entry
of innovative medicines
Service
Contact
Downloads
Export
About this site
Copyright
Privacy
Cookies
Toegankelijkheid
Kwetsbaarheid melden
Over de Horizonscan
About the Horizon Scan
Nederlands
English